198 related articles for article (PubMed ID: 32505631)
1. Treatment of Patients With Non-Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations.
Marmarelis ME; Langer CJ
Clin Lung Cancer; 2020 Sep; 21(5):395-406. PubMed ID: 32505631
[TBL] [Abstract][Full Text] [Related]
2. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.
Tan AC; Tan DSW
J Clin Oncol; 2022 Feb; 40(6):611-625. PubMed ID: 34985916
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapy of non-small cell lung cancer.
Svaton M
Klin Onkol; 2021; 34(Supplementum 1):48-52. PubMed ID: 34154330
[TBL] [Abstract][Full Text] [Related]
4. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
[TBL] [Abstract][Full Text] [Related]
5. Targeted Therapy for Patients With Metastatic Non-Small Cell Lung Cancer.
Reckamp KL
J Natl Compr Canc Netw; 2018 May; 16(5S):601-604. PubMed ID: 29784736
[TBL] [Abstract][Full Text] [Related]
6. Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer.
Halliday PR; Blakely CM; Bivona TG
Curr Oncol Rep; 2019 Feb; 21(3):21. PubMed ID: 30806814
[TBL] [Abstract][Full Text] [Related]
7. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
[TBL] [Abstract][Full Text] [Related]
8. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
9. Expression Profiling of Driver Genes in Female Never-smokers With Non-adenocarcinoma Non-small-cell Lung Cancer in China.
Zhao Y; Dong Y; Zhao R; Zhang B; Wang S; Zhang L; Hu M; He Q; Zhang W; Han B
Clin Lung Cancer; 2020 Sep; 21(5):e355-e362. PubMed ID: 32139332
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor.
Berge EM; Doebele RC
Semin Oncol; 2014 Feb; 41(1):110-25. PubMed ID: 24565585
[TBL] [Abstract][Full Text] [Related]
11. What, When, and How of Biomarker Testing in Non-Small Cell Lung Cancer.
Riely GL
J Natl Compr Canc Netw; 2017 May; 15(5S):686-688. PubMed ID: 28515244
[TBL] [Abstract][Full Text] [Related]
12. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
[TBL] [Abstract][Full Text] [Related]
13. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC
Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220
[TBL] [Abstract][Full Text] [Related]
14. Unique Genetic Characteristics and Clinical Prognosis of Female Patients with Lung Cancer Harboring RET Fusion Gene.
Qiu Z; Ye B; Wang K; Zhou P; Zhao S; Li W; Tian P
Sci Rep; 2020 Jun; 10(1):10387. PubMed ID: 32587276
[TBL] [Abstract][Full Text] [Related]
15. Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.
Arbour KC; Riely GJ
JAMA; 2019 Aug; 322(8):764-774. PubMed ID: 31454018
[TBL] [Abstract][Full Text] [Related]
16. Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer.
Rebuzzi SE; Zullo L; Rossi G; Grassi M; Murianni V; Tagliamento M; Prelaj A; Coco S; Longo L; Dal Bello MG; Alama A; Dellepiane C; Bennicelli E; Malapelle U; Genova C
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807876
[TBL] [Abstract][Full Text] [Related]
17. Emerging targeted therapies in non-small cell lung cancer.
Khanal N; Ganti AK
Expert Rev Anticancer Ther; 2016; 16(2):177-87. PubMed ID: 26618563
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives.
Genova C; Rossi G; Tagliamento M; Rijavec E; Biello F; Cerbone L; Zullo L; Grossi F
Expert Rev Respir Med; 2020 Apr; 14(4):367-383. PubMed ID: 31917616
[No Abstract] [Full Text] [Related]
19. [Targeted therapy and precision medicine : More than just words in the treatment of lung cancer].
Heigener DF; Horn M; Reck M
Internist (Berl); 2016 Dec; 57(12):1243-1249. PubMed ID: 27587193
[TBL] [Abstract][Full Text] [Related]
20. Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer.
Califano R; Abidin A; Tariq NU; Economopoulou P; Metro G; Mountzios G
Cancer Treat Rev; 2015 May; 41(5):401-11. PubMed ID: 25842168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]